isomethyleugenol has been researched along with Triple Negative Breast Neoplasms in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 9 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baudre, L; Baulande, S; Bento, ST; Bohec, M; Dahmani, A; Durand, A; Eisele, A; Foulon, S; Grosselin, K; Landragin, C; Letouzé, E; Lyne, AM; Marangoni, E; Marsolier, J; Perié, L; Prompsy, P; Salomon, AV; Sourd, L; Trouchet, A; Vallot, C | 1 |
| Chen, N; Han, J; He, J; Shen, X; Zhong, J | 1 |
| Dent, RA; Fink, JL; Jaradi, B; Koo, KM; Stone, N; Tan, DS; Tan, PH; Tan, TJ; Tay, TK; Waring, P | 1 |
| Batbayar, G; Horike, SI; Ishimura, A; Lyu, H; Meguro-Horike, M; Suzuki, T; Takino, T; Terashima, M; Wanna-Udom, S | 1 |
| Chen, Y; Gao, L; He, Y; Kong, X; Li, G; Li, Q; Li, Y; Liu, Y; Long, Q; Pu, P; Tong, S; Yang, Y; Zhang, J | 1 |
| Ball, LE; Brobbey, C; Delaney, JR; Gan, W; Howe, PH; Liu, L; Yin, S | 1 |
| Gao, G; Liang, JY; Liu, P; Tang, H; Xie, X; Yang, A; Yang, L; Zheng, S; Zou, Y | 1 |
| Byun, WS; Jarhad, DB; Jeong, LS; Kim, WK; Lee, SK; Yoon, JS | 1 |
| Cho, JY; Kim, H; Lee, KH; Park, HM | 1 |
| Fan, H; Feng, J; Li, J; Liu, C; Meng, Z; Peng, Y; Wang, L; Yuan, L; Zhao, W; Zheng, Q | 1 |
| Cao, Z; Chen, L; Davidson, NE; Fu, Y; Huang, M; Huang, Y; Lu, B; Oesterreich, S; Qin, Y; Vasilatos, SN; Vlad, AM; Wu, H | 1 |
| Chang, S; Geng, C; Lian, Y; Liu, F; Liu, S; Ma, C; Meng, L; Sang, M | 1 |
12 other study(ies) available for isomethyleugenol and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
H3K27me3 conditions chemotolerance in triple-negative breast cancer.
Topics: Drug Resistance, Neoplasm; Histones; Humans; Lysine; Methylation; Neoplasm Recurrence, Local; Triple Negative Breast Neoplasms | 2022 |
Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Topics: Humans; Hypoxia; Methylation; Prognosis; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2022 |
Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for
Topics: BRCA1 Protein; Genes, BRCA1; Humans; Methylation; Platinum; Triple Negative Breast Neoplasms | 2022 |
ASH2L, a COMPASS core subunit, is involved in the cell invasion and migration of triple-negative breast cancer cells through the epigenetic control of histone H3 lysine 4 methylation.
Topics: DNA-Binding Proteins; Epigenesis, Genetic; Histone-Lysine N-Methyltransferase; Histones; Humans; Lysine; Methylation; Nuclear Proteins; Transcription Factors; Triple Negative Breast Neoplasms | 2023 |
SETD7 promotes metastasis of triple-negative breast cancer by YY1 lysine methylation.
Topics: Cell Proliferation; Female; Histone-Lysine N-Methyltransferase; Humans; Lysine; Methylation; Protein Processing, Post-Translational; Triple Negative Breast Neoplasms; YY1 Transcription Factor | 2023 |
Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer.
Topics: Autophagy; Enzyme Inhibitors; Humans; Methylation; Protein-Arginine N-Methyltransferases; Triple Negative Breast Neoplasms | 2023 |
Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer.
Topics: Animals; Cell Line, Tumor; Female; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Lymphangiogenesis; Methylation; Mice, Nude; Neoplasm Invasiveness; RNA, Long Noncoding; Transcriptional Activation; Triple Negative Breast Neoplasms | 2020 |
Antiproliferative and Antimigration Activities of Fluoro-Neplanocin A via Inhibition of Histone H3 Methylation in Triple-Negative Breast Cancer.
Topics: Adenosine; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Halogenation; Histone-Lysine N-Methyltransferase; Histones; Humans; Methylation; Triple Negative Breast Neoplasms | 2020 |
Analysis of opposing histone modifications H3K4me3 and H3K27me3 reveals candidate diagnostic biomarkers for TNBC and gene set prediction combination.
Topics: Biomarkers, Tumor; Cells, Cultured; Female; Histones; Humans; Methylation; ROC Curve; Triple Negative Breast Neoplasms | 2020 |
Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
Topics: Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p57; F-Box Proteins; Gene Expression Regulation, Neoplastic; Histones; Humans; Jumonji Domain-Containing Histone Demethylases; Lysine; Methylation; Promoter Regions, Genetic; Protein Binding; RNA Interference; Triple Negative Breast Neoplasms | 2018 |
Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chemokines; Female; Histone Code; Histone Deacetylase Inhibitors; Histone Demethylases; Humans; Immunotherapy; Methylation; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Programmed Cell Death 1 Receptor; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Triple Negative Breast Neoplasms; Tumor Escape; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Methylation; Mice; Mice, Inbred BALB C; Mice, Nude; Poly (ADP-Ribose) Polymerase-1; Random Allocation; Receptors, Androgen; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |